ON NORMALIZING OF URINARY KIM-1 LEVEL TO URINE CREATININE IN PATIENTS WITH RENAL CELL CANCER

KIM-1 (kidney injury molecule 1), a marker of acute kidney injury, is produced by epithelial cells of renal proximal tubules. Elevated KIM-1 levels in urine and plasma are associated with renal cell carcinoma (RCC). The aim of this study was to compare the significance of non-normalized uKIM-1 values and those normalized to urine creatinine, as urinary biomarkers in RCC. The uKIM-1, urine creatinine and their ratio (uKIM-1/Cre) were studied in 118 RCC patients and 58 apparently healthy subjects. The median of uKIM-1 in the healthy group was 0.71 ng/ml (1st and 3rd quartiles were 0.35 and 1.23, respectively) and in RCC patients it was 2.36 (1.43; 5.93) ng/ml. The medians of uKIM-1/Cre were 0.77 (0.49; 1.18) and 2.42 (1.41; 4.61) ng/mgCre, respectively. Stage I RCC is statistically significantly different from stages II-III and stage IV using uKIM-1/Cre values (p = 0.0056 and p = 0.0012, respectively); using uKIM-1 values significant differences occur only when comparing stages I and IV (p = 0.015). In both healthy individuals and RCC patients, uKIM-1/Cre levels were slightly lower in subgroups younger than 50 years than in subgroups older than 50 years, whereas a similar trend was observed for uKIM-1 only in patients. In healthy men and male patients, uKIM-1 levels were higher than in the corresponding groups of women (the differences were not statistically significant), but the use of uKIM-1/Cre values eliminated the gender differences. A high correlation was found between the concentrations of uKIM-1 and urine creatinine in three healthy subjects followed up for 3 weeks (Spearman’s correlation coefficients were 0.758, 0.825 and 0.933, respectively). The data obtained are clear evidence of the need for normalization uKIM-1 to urine creatinine in RCC patients.

Kaprin A.D., Starinskij V.V., Petrova G.V., eds. Malignant neoplasms in Russia in 2018. Moscow. P.А. Hertsen Moscow Oncology Research Institute, Branch of NMRC of Radiology, Ministry of Health of the Russian Federation; 2019. (in Russian)

Cancer of kidney parenchyma. Clinical guidelines. Ministry of Health of the Russian Federation. Available at: http://www.oncology.ru/association/clinical-guidelines/2018/rak_pochki_pr2018.pdf. (in Russian)

Ichimura T., Bonventre J.V., Bailly V., Wei H., Hession C.A., Cate R.L. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 1998; 273(7): 4135-42. https://doi.org/10.1074/jbc.273.7.4135

Bonventre J.V. Kidney injury molecule-1: a translational journey. Trans. Am. Clin. Climatol. Assoc. 2014; 125: 293-9; discussion 299.

Griffin B.R., Faubel S., Edelstein C.L. Biomarkers of drug-induced kidney toxicity. Ther. Drug. Monit. 2019; 41(2): 213-26. https://doi.org/10.1097/FTD.0000000000000589

Waikar S.S., Sabbisetti V., Ärnlöv J., Carlsson A.C., Coresh J., Feldman H.I. et al. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol. Dial. Transplant. 2016; 31(9): 1460-70. https://doi.org/10.1093/ndt/gfw203

Moresco R.N., Bochi G.V., Stein C.S., De Carvalho J.A.M., Cembranel B.M., Bollick Y.S. Urinary kidney injury molecule-1 in renal disease. Clin Chim Acta. 2018;487:15-21, https://doi.org/10.1016/j.cca.2018.09.011

Han W.K., Alinani A., Wu C.L., Michaelson D., Loda M., McGovern F.J. et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J. Am. Soc. Nephrol. 2005; 16(4): 1126-34. https://doi.org/10.1681/ASN.2004070530

Morrissey J.J., London A.N., Lambert M.C. Kharasch E.D. Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma. Am. J. Nephrol. 2011; 34(5): 391–8, https://doi.org/10.1159/000330851

Mijuskovic M., Stanojevic I., Milovic N., Cerovic S., Petrovic D., Maksic D. et al. Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma. Int. Urol. Nephrol. 2018; 50(1) : 63–70. https://doi.org/10.1007/s11255-017-1724-6

Kanukoev K.Yu., Sergeeva N.S., Karmakova T.A., Marshutina N.V., Solohina M.P., Nyushko K.M. et al. KIM-1 (kidney injury molecule 1) in the urine of renal cell carcinoma patients. Onkourologiya. 2020; 16(3): 21–8. https://doi.org/10.17650/1726-9776-2020-16-3-21-28 (in Russian)

Scelo G., Muller D.C., Riboli E., Johansson M., Cross A.J., Vineis P. et al. KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. Clin. Cancer Res. 2018; 24(22): 5594–5601. https://doi.org/10.1158/1078-0432.CCR-18-1496

Gershtein E.S., Naberezhnov D.S., Alferov A.A., Bezhanova S.D., Frolova N.F., Matveev V.B. et al. Clinical implication of kidney injury molecule (KIM-1) in blood plasma of renal-cell cancer patients. Onkourologiya. 2020; 16(4):39-47. https://doi.org/10.17650/1726-9776-2020-16-4-39-47 (in Russian)

George B., Wen X., Mercke N., Gomez M., O’Bryant C., Bowles D.W. et al. Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy. Toxicol. Rep. 2020; 7: 571-6. https://doi.org/10.1016/j.toxrep.2020.04.003

Ghadrdan E., Ebrahimpour S., Sadighi S., Chaibakhsh S., Jahan­gard-Rafsanjani Z. Evaluation of urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule-1 as biomarkers of renal function in cancer patients treated with cisplatin. J. Oncol. Pharm. Pract. 2020; 26(7): 1643-49. https://doi.org/10.1177/1078155220901756

Shinke H., Masuda S., Togashi Y., Ikemi Y., Ozawa A., Sato T. et al. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother. Pharmacol. 2015; 76(5): 989-96. https://doi.org/10.1007/s00280-015-2880-y

Shao X., Tian L., Xu W., Zhang Z., Wang C., Qi C. et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014; 9(1): e84131. https://doi.org/10.1371/journal.pone.0084131

Maeda A., Ando H., Ura T., Muro K., Aoki M., Saito K. et al. Differences in urinary renal failure biomarkers in cancer patients initially treated with cisplatin. Anticancer Res. 2017; 37(9): 5235-9. https://doi.org/10.21873/anticanres.11947

Waikar S.S., Sabbisetti V.S., Bonventre J.V. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010; 78(5): 486-94. https://doi.org/10.1038/ki.2010.165

Perucca J., Bouby N., Valeix P., Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;292(2):R700-5. https://doi.org/10.1152/ajpregu.00500.2006

Ichimura T., Hung C.C., Yang S.A., Stevens J.L., Bonventre J.V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal. Physiol. 2004; 286(3): F552-F563. https://doi.org/10.1152/ajprenal.00285.2002

Zhang P.L., Rothblum L.I., Han W.K., Blasick T.M., Potdar S., Bonventre J.V. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 2008; 73: 608-14. https://doi.org/10.1038/sj.ki.5002697

Musso C.G., Michelángelo H., Vilas M., Reynaldi J., Martinez B., Algranati L. et al. Creatinine reabsorption by the aged kidney. Int. Urol. Nephrol. 2009; 41(3): 727-31. https://doi.org/10.1007/s11255-008-9508-7

Huang Y., Tian Y., Likhodii S., Randell E. Baseline urinary KIM-1 concentration in detecting acute kidney injury should be interpreted with patient pre-existing nephropathy. Pract. Lab. Med. 2019; 15:e00118. https://doi.org/10.1016/j.plabm.2019.e00118

Pennemans V., Rigo J.M., Faes C., Reynders C., Penders J., Swennen Q. Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population: are age and gender an issue? Clin. Chem. Lab. Med. 2013; 51(9): 1795-802. https://doi.org/10.1515/cclm-2013-0157